Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus

LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA and GERARD ESPINOSA
The Journal of Rheumatology September 2014, 41 (9) 1895-1896; DOI: https://doi.org/10.3899/jrheum.140080
LAURA MAGNANO
Department of Hematology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HECTOR ENRÍQUEZ
Department of Autoimmune Diseases;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JORDI ESTEVE
Department of Hematology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICARD CERVERA
Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERARD ESPINOSA
Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gespino@clinic.ub.es
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Thrombocytopenia is frequent in patients with systemic lupus erythematosus (SLE), occurring in 7% to 30% of patients. Less than 5% present a platelet count of < 50,000/mm3 and they usually respond to first- or second-line therapy [corticosteroids, immunosuppressive agents, intravenous immunoglobulin (IVIG), rituximab, or splenectomy]. However, a significant number of patients will not respond to these treatments or will relapse afterward1.

Romiplostim and eltrombopag are 2 thrombopoietin-receptor agonist drugs that were approved in 2008 by the US Food and Drug Administration (FDA) to treat patients with chronic idiopathic thrombocytopenic purpura who have an insufficient response to conventional therapy2,3,4,5. To date, there are only 4 published cases of patients with SLE and immune thrombocytopenia successfully treated with these agents6,7,8,9 and 1 case in whom this treatment was not effective10. We describe 2 additional cases of patients with SLE and refractory immune thrombocytopenia who responded to thrombopoietin-receptor agonists.

Case 1

A 69-year-old woman was diagnosed with SLE in 1992 because of anemia, thrombocytopenia, positive antinuclear antibody (ANA), anti-dsDNA, anti-Sm antibodies, lupus anticoagulant, and hypocomplementemia. In 1999, a laparoscopic splenectomy was performed because of severe immune thrombocytopenia (< 10,000/mm3) that was refractory to high-dose prednisone and IVIG. She maintained a normal platelet count until March 2013 when she presented with mild epistaxis, ecchymosis, and thrombocytopenia of 22,000/mm3 without …

Address correspondence to Dr. G. Espinosa, Servei de Malalties Autoimmunes, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain. E-mail: gespino{at}clinic.ub.es

View Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 9
1 Sep 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA, GERARD ESPINOSA
The Journal of Rheumatology Sep 2014, 41 (9) 1895-1896; DOI: 10.3899/jrheum.140080

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus
LAURA MAGNANO, HECTOR ENRÍQUEZ, JORDI ESTEVE, RICARD CERVERA, GERARD ESPINOSA
The Journal of Rheumatology Sep 2014, 41 (9) 1895-1896; DOI: 10.3899/jrheum.140080
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Case 1
    • Case 2
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire